NASDAQ · FTH
Faeth Therapeutics, Inc.
$28.29 +$0.53 (+1.91%) 1D After hoursKey Metrics
$729.28M
Market cap
—
P/E · TTM
—
Revenue · TTM
−$163.37M
Net income
EPS · TTM
$-129.71
Dividend yield
—
Free cash flow
—
Beta · 1Y
—
EBITDA · TTM
—
Gross margin
—
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 23
A material event was filed (Form 8-K).
8-K - Faeth Therapeutics, Inc. (0001829802) (Filer)
RECEIPT: SEC FORM 8-K, TIMESTAMPED -
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE
The story updates itself as events post · The wolf reports; you decide
Snapshot
Market cap$729.28M
Enterprise value—
Shares outstanding25.8M
52-wk range$13.43 – $37.90
Avg volume · 20D211.4K
Net cash
—
Book value / share$-109.00
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Faeth Therapeutics, Inc.
IPO dateFeb 4, 2021
Employees29
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways.
Wolf Grade COMING SOON
—
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.
Valuation
P/E—
P/S—
P/FCF—
EV/EBITDA—
EV/Sales—
Graham №—
Profitability
Gross
—
Operating
—
Net
—
FCF
—
ROE / ROIC
330.4% · —
Financial Health
Current ratio14.39
Quick ratio—
Debt / equity—
Debt / EBITDA
—
Net cash
—
Working capital$190.04M
Cash Flow · TTM
Operating CF
—
Capex
—
Free cash flow
—
Buybacks
—
Dividends paid
—
Shareholder yield
—
Piotroski F-Score
0 / 9
Weak fundamentals · 0 of 9 signals passing
Altman Z-Score
—
Insufficient balance-sheet inputs
Graham Number vs Price
—
Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings